EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial

Peter G Pappas, Jose A Vazquez, Ilana Oren, Galia Rahav iD, Mickael Aoun, Pierre Bulpa, Ronen Ben-Ami, Ricard Ferrer, Todd Mccarty, George R Thompson iD, Haran Schlamm, Paul A Bien und 5 weitere

Journal of Antimicrobial Chemotherapy · 03.10.2023 · 78 (10) · 2471-2480

DOI: 10.1093/jac/dkad256 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 19.08.2023. Verfasst von Peter G Pappas und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Candidemia. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Amplyx, Pfizer Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fosmanogepix is a first-in-class antifungal targeting the fungal enzyme Gwt1, with broad-spectrum activity against yeasts and moulds, including multidrug-resistant fungi, formulated for intravenous (IV) and oral administration.

Methods

This global, multicenter, non-comparative study evaluated the safety and efficacy of fosmanogepix for first-line treatment of candidaemia in non-neutropenic adults. Participants with candidaemia, defined as a positive blood culture for Candida spp. within 96 h prior to study entry, with ≤2 days of prior systemic antifungals, were eligible. Participants received fosmanogepix for 14 days: 1000 mg IV twice daily on Day 1, followed by maintenance 600 mg IV once daily, and optional switch to 700 mg orally once daily from Day 4. Eligible participants who received at least one dose of fosmanogepix and had confirmed diagnosis of candidaemia (<96 h of treatment start) composed the modified intent-to-treat (mITT) population. Primary efficacy endpoint was treatment success at the end of study treatment (EOST) as determined by the Data Review Committee. Success was defined as clearance of Candida from blood cultures with no additional antifungal treatment and survival at the EOST.

Results

Treatment success was 80% (16/20, mITT; EOST) and Day 30 survival was 85% (17/20; 3 deaths unrelated to fosmanogepix). Ten of 21 (48%) were switched to oral fosmanogepix. Fosmanogepix was well tolerated with no treatment-related serious adverse events/discontinuations. Fosmanogepix had potent in vitro activity against baseline isolates of Candida spp. (MICrange: CLSI, 0.002–0.03 mg/L).

Conclusions

Results from this single-arm Phase 2 trial suggest that fosmanogepix may be a safe, well-tolerated, and efficacious treatment for non-neutropenic patients with candidaemia, including those with renal impairment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsCandidemiaAdultHumansFungiCandidaTreatment Outcome

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Division of Infectious Disease, Department of Medicine, Medical College of Georgia/Augusta University, Augusta, GA, USA.
  • Infectious Disease Unit, Rambam Health Care Campus, Haifa, Israel.
  • Sheba Medical Center, Ramat Gan, Israel.
  • Chaim Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Department of Internal Medicine, Institut Jules Bordet, Brussels, Belgium.

ORCID-Profile: Galia Rahav, George R Thompson, Margaret Tawadrous

Förderung

  • Amplyx
  • Pfizer Inc

Zitieren

APA

Pappas, P. G., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., Mccarty, T., Thompson, G. R., Schlamm, H., Bien, P. A., Barbat, S. H., Wedel, P., Oborska, I., Tawadrous, M., & Hodges, M. R. (2023). Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial. Journal of Antimicrobial Chemotherapy, 78(10), 2471-2480. https://doi.org/10.1093/jac/dkad256

Vancouver

Pappas PG, Vazquez JA, Oren I, Rahav G, Aoun M, Bulpa P, et al. Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial. Journal of Antimicrobial Chemotherapy. 2023;78(10):2471-2480. doi:10.1093/jac/dkad256

BibTeX
@article{Pappas2023,
  author = {Pappas, Peter G and Vazquez, Jose A and Oren, Ilana and Rahav, Galia and Aoun, Mickael and Bulpa, Pierre and Ben-Ami, Ronen and Ferrer, Ricard and Mccarty, Todd and Thompson, George R and Schlamm, Haran and Bien, Paul A and Barbat, Sara H and Wedel, Pamela and Oborska, Iwona and Tawadrous, Margaret and Hodges, Michael R},
  title = {Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  volume = {78},
  number = {10},
  pages = {2471--2480},
  doi = {10.1093/jac/dkad256}
}
Kostenlos starten →